Britain and America have hammered out a major trade agreement that will guarantee no duties on UK drug products going into the American market.
The Terms of the Pact
Under the terms of the agreement, the UK has pledged to boost spending on drugs through the public health system. This pledge secures that import taxes on these vital products will remain at nothing for a duration of three years.
This deal comes after earlier statements to significantly raise tariffs on patented drug imports, with potential rates mentioned reaching double the cost.
"This agreement between the UK bolsters the global environment for cutting-edge drugs and establishes long-overdue equity to U.S.–U.K. medicine commerce," a release noted.
Trade Impact
Pharmaceuticals constitute one of the Britain's largest exports to the United States, which is clearly the biggest destination for large companies like GSK and AstraZeneca.
Trade data indicate that in the one-year period leading up to last September, the UK sold medicines valued at £11.1bn to the US. This value represented a significant portion of all goods exports in that period.
"This deal safeguards employment, stimulates funding and paves the way for the UK to become a worldwide center for life sciences," a minister stated.
Key UK Commitments
The deal entails several notable commitments from the UK:
- Price Threshold Increase: The UK will increase the price threshold at which it judges new medicines to be unaffordable by twenty-five percent.
- Boosted Medicine Funding: There is a goal to double total NHS spending on treatments from 0.3 percent of the national economy to 0.6 percent over the coming ten years.
- Payback Limit: The amount drug companies must pay back to the NHS to control costs will be restricted at fifteen percent. Last year, rebates exceeded 20%.
Industry Background
The pact comes amid a protracted dispute between the sector and the ministers over drug pricing and approval rates.
This friction were intensified by arguments that US patients were paying several times more for the equivalent treatments than people in the Britain and the EU.
Recently, several major manufacturing plans in the UK have been delayed or scrapped, while major investments have been pledged toward American operations.
One official stated that the NHS needed to spend more on medicines, noting that its expenditure on drugs had shrunk as a proportion of its total funding over the previous ten-year period.
